Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 12/20 | 0.45 |
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | HTR2B | P41595 | 3/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26508210 | 0.89 | MTNR1A (0.47) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL25253115 | 0.84 | HTR2A (0.62) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL27084736 | 0.84 | HTR2A (0.62) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL26508296 | 0.84 | HTR2A (0.63) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL26508319 | 0.83 | MTNR1A (0.46) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL26508182 | 0.82 | HTR2A (0.45) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL26508194 | 0.81 | HTR2A (0.46) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL26508198 | 0.81 | MTNR1A (0.46) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL26508216 | 0.81 | HTR2A (0.67) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL26508200 | 0.81 | MTNR1A (0.47) | MTNR1AMTNR1BHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322735-A1 | AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322735-A1 | AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322735-A1 | AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS | TPH2, TPH1, HTR2A | MTNR1A 75/4885MTNR1B 50/4885HTR2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.